Positive News Sentiment NASDAQ:ASLN ASLAN Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ASLAN Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. $0.58 +0.07 (+13.73%) (As of 07/5/2022 12:00 AM ET) Add Compare Share Today's Range$0.53▼$0.6050-Day Range$0.36▼$0.7052-Week Range$0.36▼$3.81Volume369,215 shsAverage Volume319,372 shsMarket Capitalization$40.46 millionP/E RatioN/ADividend YieldN/APrice Target$6.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media ASLAN Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside992.0% Upside$6.33 Price TargetShort InterestBearish2.03% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.66) to ($0.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.90 out of 5 starsMedical Sector623rd out of 1,426 stocksPharmaceutical Preparations Industry301st out of 682 stocks 3.4 Analyst's Opinion Consensus RatingASLAN Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.33, ASLAN Pharmaceuticals has a forecasted upside of 992.0% from its current price of $0.58.Amount of Analyst CoverageASLAN Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.03% of the float of ASLAN Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverASLAN Pharmaceuticals has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in ASLAN Pharmaceuticals has recently increased by 12.82%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldASLAN Pharmaceuticals does not currently pay a dividend.Dividend GrowthASLAN Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ASLN. Previous Next 3.8 News and Social Media Coverage News SentimentASLAN Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ASLAN Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for ASLN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added ASLAN Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ASLAN Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 38.65% of the stock of ASLAN Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ASLAN Pharmaceuticals are expected to decrease in the coming year, from ($0.66) to ($0.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ASLAN Pharmaceuticals is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ASLAN Pharmaceuticals is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioASLAN Pharmaceuticals has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ASLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ASLAN Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About ASLAN Pharmaceuticals (NASDAQ:ASLN) StockASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.Read More ASLN Stock News HeadlinesJune 25, 2022 | americanbankingnews.comASLAN Pharmaceuticals (NASDAQ:ASLN) Stock Rating Reaffirmed by HC WainwrightJune 7, 2022 | finance.yahoo.comASLAN Pharmaceuticals Initiates Scientific Collaboration to Investigate the Distinct Role of IL-13 Receptor Signaling in Atopic DermatitisJune 6, 2022 | finance.yahoo.comASLAN Pharmaceuticals to Host Third Webinar in A⁴ KOL Series: ‘Dialogues With International Thought Leaders in Dermatology’May 31, 2022 | finance.yahoo.comASLAN Pharmaceuticals to Participate in Fireside Chat at Jefferies Global Healthcare ConferenceMay 20, 2022 | finance.yahoo.comASLAN Pharmaceuticals Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Mechanisms at the 2022 Society for Investigative Dermatology Annual MeetingMay 18, 2022 | finance.yahoo.comASLAN Pharmaceuticals to Present at the H.C. Wainwright Global Investment ConferenceMay 10, 2022 | finance.yahoo.comASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab and Neuronal Itch Mechanisms for Poster Presentation at the 2022 Society for Investigative Dermatology Annual MeetingApril 27, 2022 | seekingalpha.comASLAN Pharmaceuticals GAAP EPADS of -$0.19 misses by $0.01April 27, 2022 | finance.yahoo.comASLAN Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdateApril 6, 2022 | finance.yahoo.comASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 2022April 1, 2022 | finance.yahoo.comASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementMarch 28, 2022 | finance.yahoo.comASLAN Pharmaceuticals Announces Late-Breaker Presentation of Data From Eblasakimab Proof-of-Concept Study at the 2022 American Academy of Dermatology Annual MeetingMarch 26, 2022 | seekingalpha.comASLAN Pharmaceuticals GAAP EPS of -$0.03March 25, 2022 | finance.yahoo.comASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateMarch 18, 2022 | finance.yahoo.comASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab Proof-of-Concept Study in Atopic Dermatitis for Oral Presentation at the 2022 American Academy of Dermatology Annual MeetingMarch 15, 2022 | finance.yahoo.comASLAN Pharmaceuticals Appoints Dermatology Veteran Dr Alex Kaoukhov as Chief Medical OfficerMarch 13, 2022 | realmoney.thestreet.comAslan Pharmaceuticals Ltd. (ASLN)March 4, 2022 | in.investing.comAslan Pharmaceuticals Ltd (6497)January 21, 2022 | finance.yahoo.comASLAN (ASLN) Starts Phase IIb Study in Atopic DermatitisJanuary 20, 2022 | seekingalpha.comAslan Pharmaceuticals begins phase2b study of ASLAN004 for eczemaJanuary 20, 2022 | finance.yahoo.comASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic DermatitisJanuary 18, 2022 | finance.yahoo.comASLAN Pharmaceuticals to Host New Episode in A4 KOL Series: Aspects of Atopic Dermatitis and ASLAN004January 11, 2022 | finance.yahoo.comASLAN Pharmaceuticals to Present Additional Data From Aslan004 Proof-Of-Concept Study at Two Upcoming Winter Dermatology ConferencesJanuary 11, 2022 | finance.yahoo.comASLAN Pharmaceuticals to Present Additional Data From Aslan004 Proof-Of-Concept Study at Two Upcoming Winter Dermatology ConferencesJanuary 6, 2022 | finance.yahoo.comASLAN Pharmaceuticals to Present at H.C. Wainwright Bioconnect Conference 2022See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ASLN CUSIPN/A CIK1722926 Webwww.aslanpharma.com Phone65-6222-4235Fax65-6225-2419Employees18Year FoundedN/ACompany Calendar Last Earnings4/27/2022Today7/05/2022Next Earnings (Estimated)8/05/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$6.33 High Stock Price Forecast$8.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+992.0%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-58.72% Return on Assets-37.34% Debt Debt-to-Equity Ratio0.81 Current Ratio9.63 Quick Ratio9.63 Sales & Book Value Annual Sales$3 million Price / Sales13.49 Cash FlowN/A Price / Cash FlowN/A Book Value$0.82 per share Price / Book0.71Miscellaneous Outstanding Shares69,750,000Free FloatN/AMarket Cap$40.46 million OptionableNot Optionable Beta2.04 ASLAN Pharmaceuticals Frequently Asked Questions Should I buy or sell ASLAN Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ASLAN Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ASLAN Pharmaceuticals stock. View analyst ratings for ASLAN Pharmaceuticals or view top-rated stocks. What is ASLAN Pharmaceuticals' stock price forecast for 2022? 4 brokers have issued 1-year price objectives for ASLAN Pharmaceuticals' shares. Their ASLN stock forecasts range from $3.00 to $8.00. On average, they expect ASLAN Pharmaceuticals' stock price to reach $6.33 in the next year. This suggests a possible upside of 992.0% from the stock's current price. View analysts' price targets for ASLAN Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has ASLAN Pharmaceuticals' stock performed in 2022? ASLAN Pharmaceuticals' stock was trading at $1.12 on January 1st, 2022. Since then, ASLN shares have decreased by 48.2% and is now trading at $0.58. View the best growth stocks for 2022 here. When is ASLAN Pharmaceuticals' next earnings date? ASLAN Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022. View our earnings forecast for ASLAN Pharmaceuticals. How were ASLAN Pharmaceuticals' earnings last quarter? ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) posted its earnings results on Wednesday, April, 27th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.02. View ASLAN Pharmaceuticals' earnings history. Who are ASLAN Pharmaceuticals' key executives? ASLAN Pharmaceuticals' management team includes the following people: Dr. Carl Alan Jason Morton Firth EMBA, Ph.D., Founder, CEO & Exec. Director (Age 49)Mr. Kiran Kumar Asarpota, COO & Head of Fin. (Age 43)Mr. Ben Goodger, Gen. Counsel (Age 59)Mr. Stephen Doyle, Chief Bus. Officer (Age 49)Charlie Hsu, Investor Relations DirectorChi-Chin Wang, IR & Corp. Devel. DirectorDr. Alexandre Kaoukhov M.D., Chief Medical Officer (Age 48) Who are some of ASLAN Pharmaceuticals' key competitors? Some companies that are related to ASLAN Pharmaceuticals include ObsEva (OBSV), Viracta Therapeutics (VIRX), scPharmaceuticals (SCPH), F-star Therapeutics (FSTX), Longeveron (LGVN), Endo International (ENDP), Rain Therapeutics (RAIN), Satsuma Pharmaceuticals (STSA), Immuneering (IMRX), Citius Pharmaceuticals (CTXR), IO Biotech (IOBT), Trevi Therapeutics (TRVI), NextCure (NXTC), Anebulo Pharmaceuticals (ANEB) and Atossa Therapeutics (ATOS). View all of ASLN's competitors. What other stocks do shareholders of ASLAN Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ASLAN Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Onconova Therapeutics (ONTX), Aldeyra Therapeutics (ALDX), SCYNEXIS (SCYX) and VBI Vaccines (VBIV). When did ASLAN Pharmaceuticals IPO? (ASLN) raised $60 million in an IPO on Friday, May 4th 2018. The company issued 7,500,000 shares at a price of $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers. What is ASLAN Pharmaceuticals' stock symbol? ASLAN Pharmaceuticals trades on the NASDAQ under the ticker symbol "ASLN." How do I buy shares of ASLAN Pharmaceuticals? Shares of ASLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ASLAN Pharmaceuticals' stock price today? One share of ASLN stock can currently be purchased for approximately $0.58. How much money does ASLAN Pharmaceuticals make? ASLAN Pharmaceuticals (NASDAQ:ASLN) has a market capitalization of $40.46 million and generates $3 million in revenue each year. The company earns $-31,320,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. How many employees does ASLAN Pharmaceuticals have? ASLAN Pharmaceuticals employs 18 workers across the globe. How can I contact ASLAN Pharmaceuticals? ASLAN Pharmaceuticals' mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The official website for ASLAN Pharmaceuticals is www.aslanpharma.com. The company can be reached via phone at 65-6222-4235, via email at investor@aslanpharma.com, or via fax at 65-6225-2419. This page (NASDAQ:ASLN) was last updated on 7/6/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
